Minretumomab

Minretumomab (CC49) is a mouse monoclonal antibody^[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.^[2][3] Apparently, it never got past Phase I clinical trials for this purpose.^[4]

Minretumomab

Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Clinical data
Other names	CC49
ATC code	V09IX03 (WHO) (125I radiolabelled)
Identifiers
CAS Number	195189-17-4 N
ChemSpider	none
UNII	235435CH6L
NY (what is this?)  (verify)

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric^[5] and humanized minretumomab,^[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.^[7]

Radiopharmaceuticals

Iodine (¹²⁵I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.^[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (¹³¹I) and lutetium (¹⁷⁷Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.^[5]